• CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer
• CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end
• The company is also preparing the interim study analysis for release by year’s end, now that more than 50 percent of the planned patient roster has reached a point necessary for effective comparison of performance of the flagship drug, Berubicin, to that of a standard of care chemotherapy agent
• The company has stated that it took longer than anticipated to launch the interim analysis because many patients were living longer than historical expectations, and CNS hopes to show that Berubicin has helped patients achieve a longer Overall Survival (“OS”), driving eventual commercialization and improved treatments

Cancer drug developer CNS Pharmaceuticals (NASDAQ: CNSP) is closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”), with 200 of the expected 243 patients now enrolled in the company’s potentially pivotal study involving its flagship drug candidate Berubicin, according to a company news release (https://ibn.fm/OqKzk).

The Texas-based company has clinical trial sites operating in the U.S., Italy, France, Spain, and Switzerland, to evaluate Berubicin’s performance against standard of care alkylating chemotherapy agent Lomustine for treating recurrent GBM.

GBM has been generally untreatable by anthracyclines because of their inability to cross the blood-brain barrier, but Berubicin is believed to be able to cross the barrier and directly target central nervous system tumors.

CNS Pharmaceuticals’ progress in enrolling patients for its potentially pivotal, global clinical trial indicate the company is on track to not only complete enrollment by the end of the year, but also to issue its planned futility interim analysis by the end of the year.

The interim analysis was triggered when at least 50 percent of the enrolled patients had reached the pre-planned primary efficacy endpoint, allowing an independent Data Safety Monitoring Board (“DSMB”) to review the number of deaths in each arm of the trial to ensure that the overall survival of patients receiving Berubicin shows at least a statistically significant comparison to those receiving Lomustine.

The news release notes that Overall Survival (“OS”) is a rigorous endpoint that the U.S. Food and Drug Administration (“FDA”) has recognized as the basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm, and the DSMB’s review will consider making recommendations on whether to continue the study as planned or to modify it based on patient outcomes thus far.

CNS announced last month that it has taken longer than planned to reach the endpoint for launching the interim analysis because “many patients in this study are living longer than the historical data would suggest they should,” which means it took longer to reach the number of mortality events required to conduct the interim analysis (https://ibn.fm/5G4tw).

“As we have noted previously, patient volunteers and their treating clinicians are the backbone of our Berubicin development program. We are deeply sensitive to the fact that these brave patients are facing the battle of their lives and we are forever in their debt for the trust and confidence they and their treating clinicians have in Berubicin and the company,” CNS CEO John Climaco stated in the most recent company statement on enrollment. “We are pleased to achieve this landmark milestone. Importantly, this takes us one step closer to bringing the study across the finish line and potentially offering an effective treatment in GBM that is safe and well tolerated.”

Berubicin was originally produced by Reata Pharmaceuticals, Inc., in 2006, and a small-scale clinical trial testing Berubicin’s safety at the time produced statistically significant improvements in the two dozen patients, including one who has remained cancer-free during the ensuing years. CNS reached an agreement with Reata in more recent years to advance development of the drug, and launched the global trial in 2021.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• XESP, through its Digital Engagement Engine(TM), is making automation, powerful data management, and an advanced workflow, more accessible to B2B companies
• The company allows businesses to offer buyers meaningful and empowering experiences, making them feel appreciated and understood, and moving them to action
• XESP understands businesses’ concerns, especially regarding the cost of automation, and continues to refine its products, integrating new features and addressing emerging customer needs, all at a more competitive price point
• By integrating new features and making new offerings, the company is staying ahead of the competition and stamping its position as a leader in the digital activation and engagement space

Electronic Servitor Publication Network (OTCQB: XESP), a market disruptor for B2B companies, is showing how unique, cutting-edge data analysis and smart technology can grow businesses and help them develop a continuous flow of customers. Through its Digital Engagement Engine(TM), the company is making advanced marketing automation, data management, and an efficient marketing workflow, more accessible to B2B companies, affording them greater reach and lift for their digital content and ensuring greater customer satisfaction and advocacy.

“The Digital Engagement Engine(TM) isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.”

Experts in the industry have noted that automation is no longer an option. With changing customer demands and preferences, big and small businesses are all being forced to embrace new technologies and ways to satisfy these demands. XESP, through its Digital Engagement Engine(TM), offers a unique value proposition for its customers.

For starters, through its offering, XESP allows businesses to generate valued experiences that resonate with buyers. This comes in the form of more efficiently proving a brand’s end value to customers and delivering focused offerings that drive conversion and loyalty. Through its technological offerings, XESP can provide businesses with tools that allow customers to feel appreciated and heard. Superior intelligent automated technologies, when used correctly, are able to identify and respond meaningfully and immediately, addressing the growing need for customers to get a response in 10 minutes or less, a huge determinant of customer satisfaction (https://ibn.fm/M1Bah).

“That meaningful interaction gives a greater relationship with your audience and trust,” noted Peter Hager, XESP’s CEO. “Ultimately, it drives greater growth in your organization and, very simply put, replicates what you do face-to-face,” he added (https://ibn.fm/RRMha).

One of the biggest concerns for businesses is the cost of investing in certain conveniences, technologies, or product offerings. It is a legitimate concern since it counts as an ongoing expense for businesses looking to earn as much profit as possible from selling their products or services. XESP understands this concern, and while its offering is competitively priced, the bottom line is a significant return on investment, one that allows a business to meet their growth and return on investment objectives.

Studies on automation in businesses have validated its importance. For instance, with email and marketing automation, it was noted that for every $1 invested, businesses get $44 back. In addition, triggered emails resulted in eight times more opens and more significant sales than typical batch email sends. This is on top of offering an affordable way to stay connected with customers, an easier way to track and measure metrics, and the benefit of having a more efficient team.

XESP continues to refine its product, integrating new features and addressing emerging customer needs. The company’s understanding of the changing dynamics in the market allows it to stay ahead of the competition, offering products and services that solve real problems and deliver on its promise. This has helped set the company apart from its peers while positioning itself as a leader in its segment.

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

GolfLync, the leading social networking platform for golfers, is thrilled to remind you about the GolfLync Pebble Beach Sweepstakes, your golden opportunity to win the golf trip of a lifetime to the iconic Pebble Beach Resorts, acclaimed as the No. 1 Golf Resort in America.

Pebble Beach Resorts, nestled on California’s breathtaking Monterey Peninsula, offers an unparalleled golfing experience. With its three Top 50 public courses, including the world-famous Pebble Beach Golf Links, golf at Pebble Beach Resorts is an unforgettable journey. From the stunning coastal views at Spanish Bay to the majestic pines of Spyglass Hill, each course presents its own unique challenges and thrills.

As the greatest public golf course in America, as rated by Golf Digest, Pebble Beach has a rich history of hosting prestigious tournaments, including the U.S. Open and, for the first time in 2023, the U.S. Women’s Open. This sweepstakes provides a once-in-a-lifetime opportunity for golf enthusiasts to immerse themselves in the world of championship golf and experience the magic of Pebble Beach firsthand.

The GolfLync Sweepstakes began on April 17 and will conclude on October 1, just before midnight. There’s still time to participate and seize your chance at winning this extraordinary golf trip. To enter, simply download the GolfLync app, available on both Android and iOS platforms, and create an account during the sweepstakes period. By doing so, you will automatically be entered for a chance to win.

The winner of the GolfLync Pebble Beach Sweepstakes will be selected through a random drawing, which will take place on October 4. Following the drawing, the fortunate winner will be notified and provided with all the details to embark on their unforgettable golf adventure at Pebble Beach Resorts.

Don’t miss out on this remarkable opportunity to tee off at one of the world’s most renowned golf destinations. Download the GolfLync app today and take your shot at winning the golf trip of a lifetime.

To review the official rules and eligibility criteria, please visit the GolfLync website: (official rules).

You can download the GolfLync app using the following links:

• Android: GolfLync – Apps on Google Play 
• iPhone: GolfLync 

For more information about GolfLync, visit GolfLync, download the app, and connect with community on Facebook, X and LinkedIn. 

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

Investors, policymakers, academicians, technologists, decision-makers, and business owners are invited to attend the ESG Forum (a Sustain SoCal event) to be held at the Cove, UCI Beall Applied Innovation, September 26, 2023. The highly anticipated event offers a unique platform for improving sustainable business practices. Committed to fostering environmental stewardship, the professionals will delve into the key aspects of Environmental, Social, and Governance (“ESG”) practices.

The ESG Forum is an exclusive event focused on fostering actionable insights and meaningful discussions with industry experts. The event provides a favorable platform for participants to learn, collaborate, and connect with business leaders. They will share insights into the key ESG factors that drive balance profitability and business success with positive environmental and social impact.

Implementing Sustainable Business Practices

The one-of-a-kind ESG Forum will provide attendees with a unique opportunity to engage with innovators and thought leaders who have implemented sustainability in their business strategies. The corporate leaders will share their case studies, best practices, and key insights into the integrated ESG principles. They will also share leading-edge technologies and solutions that will support governance structures and improve social impact.

Fostering networking and collaborations, the ESG Forum is committed to contributing towards a positive, sustainable future. The like-minded professionals will leverage this exclusive opportunity to convene and gain up-to-date knowledge about the latest compliance strategies and requirements. The forum will feature keynote addresses and panel discussions to explore unique solutions that help reduce the carbon footprint. By navigating the evolving regulatory landscape, the attendees will be well-equipped to drive innovation through ESG Integration and measure their business performance.

To learn more, please visit https://ibn.fm/ZmRcX

• Ucore Rare Metals Inc. is focused on establishing its proprietary solvent-based solution as a commercially advantageous and important alternative to standard rare earth (“REE”) processing
• U.S. Trade Representative Katherine Tai recently noted in a media interview that the REE supply chain is dependent on China for production and, to a greater degree, processing once ore has been removed from the ground
• Ucore’s development of its proprietary RapidSX(TM) REE processing solution promises an environmental impact advantage as well as advantages in cost and Western supply chain control
• Ucore also controls a rare earth mine prospect in Alaska that anticipates potentially developing someday as a new American REE source

U.S. trade policy makers continue to seek solutions to an economic power imbalance created by the modern tech industry’s dependence on The People’s Republic of China’s for certain metal elements that perform key functions in high-grade batteries.

The batteries supply power to a wide variety of technology used commonly by general consumers and government militaries alike. The near-total supply chain dependence on China for mining and, particularly, processing the ores that contain batteries’ critical rare earth metal elements (“REEs”) has become a significant source of concern among trade negotiators.

“China’s dominant position in the world market now in [rare earths] means that it is able to turn on the faucet and turn off the faucet,” U.S. Trade Representative Katherine Tai said during an August interview with MSNBC (https://ibn.fm/aoAai). “And until we are able to access and create additional supply chains we remain entirely vulnerable to that leverage.”

The imbalance reflects advantages nations such as China may exploit thanks to its nationalized controls over corporate operations, while Western governments maintain a more nuanced involvement in free market operations sustaining private industry.

But critical tech metal supply chain innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is attempting to become a leader in restoring REE supply chain independence to American nations through the development of a competitive REE ore processing solution that improves on the standard SX solvent-based procedures for separating REEs from the mined material they are found in.

Ucore’s proprietary RapidSX(TM) separation process is being developed as a faster, more environmentally conscious REE extraction alternative to the SX process used globally throughout the industry, and the company is preparing to begin construction this year on commercial-scale production facilities in the United States and, later, Canada.

A recent visit by U.S. Embassy staff to a Canadian Ucore facility that directly compares the output of RapidSX(TM) REEs to standard SX REEs “underscores the significance of our work in the rare earth minerals sector and highlights our dedication to pioneering eco-friendly resource solutions,” Ucore VP & COO Mike Schrider (P.E.) stated in a company news release (https://ibn.fm/0tpyt). “We believe that collaborations on an international level will play a pivotal role in shaping the future of sustainable technologies and strengthen our position of applying pioneering technological breakthroughs to bolster our forthcoming commercial rare earth separation facility in Alexandria, Louisiana.”

Tai noted a World Trade Organization case she worked on as a lawyer some years ago in which the WTO successfully objected to China’s decision to “pinch” the market for REEs. While REE prices were high, some domestic REE production resumed, but when prices again fell, American mines again shuttered their operations, she observed.

“China at some point very … smartly recognized the relevance of rare earths, and they started producing and selling to the world market at prices that we could not compete with, and our producers successively shut down,” she said. “(China was) able to pursue coordinated industrial and trade policies that allowed them to corner the market.”

Ucore’s RapidSX process aims to provide an American alternative to REE miners who must currently send their ore overseas to China for processing, and Ucore also anticipates the possibility of developing its own REE source at its Alaskan rare earth mine prospect, which holds more than 4.7 million metric tons of indicated rare earth ore — the equivalent of about 63.5 million pounds of collective rare earth metals, according to a 2015 resource assessment reported by the Alaska Journal of Commerce and shared by Sen. Lisa Murkowski (https://ibn.fm/iR3t9).

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

DGE invites biotech, pharmaceutical and medical device leaders to attend the 2nd Chief Commercial Officer Summit to be held at The Bellevue Hotel, Philadelphia, PA, October 4-5, 2023. The much-awaited summit aims to chart the remarkable future of the biotech, pharmaceutical and medical device industries. The landmark event will feature a gathering of thought leaders and visionaries dedicated to driving commercial growth in the industry.

The role of Chief Commercial Officers (“CCOs”) has gained more significance with the progression of the life sciences landscape. The 2nd Chief Commercial Officer Summit provides a unique platform to explore key strategies for advancing commercial development, improving product value, and enhancing patient access. The summit explicitly caters to the challenges of the biopharma and medical device sectors, offering customized solutions and insights to the attendees.

Focused on Market Expansion and Patient Access

The 2nd Chief Commercial Officer Summit is committed to fostering brilliance in the biopharma and medical device industries. It’s an incredible platform to build connections, gain insights, and shape the future of commercial excellence. The summit provides attendees with a unique opportunity to explore the options to access new markets and territories, opening new possibilities for expansion and growth. The industry leaders will share their strategies to ensure the profitability and success of the biopharma and medical device products.

Who will attend:

• Chief Commercial Officers
• Commercialization Experts
• Commercial Operations Professionals
• Product Launch Leaders
• Market Access Specialists
• Digital Innovators
• Reimbursement Specialists
• Marketing Executives
• Value Strategists
• Pricing Experts
• Gross-to-Net Analysts
• Franchise Leaders
• Branding Specialists
• Sales Leaders
• Finance Professionals
• Business Development Executives
• Licensing Specialists
• Venture Capitalists
• Distribution Channel Planners
• Portfolio Managers

Interested participants should register for the event now.

To learn more, please visit https://ibn.fm/7trPx.

Investors, policymakers, enthusiasts, technologists, decision-makers, and business owners are invited to attend the New Orleans Investment Conference to be held in New Orleans, Louisiana, November 1-4, 2023. The 2023 edition of this iconic event is committed to paving the way to real investment insights and financial wisdom in a fast-changing economic landscape.

Having a rich history of successful investment symposiums, the New Orleans Investment Conference has consistently brought together some of the brightest minds in finance, politics, and economics. The conference will feature a lineup of world-renowned speakers who will share valuable investment strategies to unlock the secrets of financial success.

Sharing a Legacy of Financial Success

Amidst the growing economic uncertainties, the New Orleans Investment Conference serves as a beacon of unmatched investment opportunities. The visionaries will cover a wide range of topics, from real estate, geopolitics, precious metals, and commodities to cryptocurrency, and more.

The diverse lineup of eminent thought leaders includes:

• Lyn Alden – one of today’s most insightful macro-economic analysts.
• Peter Boockvar – a respected market analyst known as the ‘resident contrarian’ on CNBC.
• Danielle DiMartino Booth – CEO and Chief Strategist at QI Research, and notably, a former Fed insider who served as an advisor to the Dallas Fed for a decade.
• Dominic Frisby – a financial writer and celebrated comedian, renowned for his YouTube presence and authorship of multiple books, including “Bitcoin: The Future of Money?”
• George Gammon – a highly successful American real estate investor, renowned for his show, “The Rebel Capitalist Show.”
• Jim Iuorio – a renowned trader and outspoken market analyst featured on CNBC and Fox News.
• Brent Johnson – CEO of Santiago Capital, famed for his dollar-milkshake theory.
• Konstantin Kisin – a popular political and lifestyle commentator with a massive global following.
• James Rickards – Editor of “Strategic Intelligence,” a financial newsletter, and author of seven best-selling books.
• Matt Taibbi – author of four New York Times bestsellers and an award-winning columnist for Rolling Stone.
• Peter Schiff – widely recognized as an economic and financial analyst who accurately forecasted the real estate bubble and the 2008 financial crisis, and the author of several best-selling books.
• Rick Rule – a global thought leader in the commodities sector, renowned as perhaps the most successful resource speculator.
• Robert Prechter – author of the classic “Elliott Wave Principle” and founder of Elliott Wave International.

From in-depth keynote presentations to interactive sessions, the New Orleans Investment Conference offers insightful financial information that spans the whole investment spectrum. Attendees will get an opportunity to connect with industry experts, like-minded investors, and visionary entrepreneurs. They can forge lasting relationships, explore economic trends, and dissect policy changes to make truly informed investment decisions.

To learn more, please visit https://ibn.fm/ISvQC

• In September 2023, Sekur Private Data announced that it had signed a distribution agreement with VYRE Network, a leading news-based streaming channel and website, for the Sekur suite of solutions
• The company has no debt and no convertible equity
• Sekur Private Data in June 2023 announced that it is on track to launch Sekur Enterprise Solutions, its new product for SMBs, large enterprises and government organizations
• The company plans to launch SekurIdentity, its new identity theft protection solution, in 2024
• Sekur Private Data plans international business expansions in Latin America, Australia and Europe in 2024

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at www.Sekur.com, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.

Products

Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

• SekurMail(R) is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
• SekurVPN(R) creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
• SekurMessenger(R) is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (“GDSA”) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

For more information, visit the company’s website at www.SekurPrivateData.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• Lexaria’s IND application builds on five previous human clinical studies showing zero serious adverse effects and evidencing a reduction in resting blood pressure in test subjects
• DehydraTECH(TM)-CBD has the potential to have pronounced clinical benefits relative to the available anti-hypertensive therapeutics on the market today
• Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the IND application
• Lexaria is waiting to submit until the necessary documentation outside of their control is ready for the IND application

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming Investigational New Drug (“IND”) submission. The application is for the company’s planned US Phase 1b Hypertension Clinical Trial HYPER-H23-1, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” looks to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM)-processed CBD in hypertensive patients.

Lexaria’s IND submission builds on five previous human clinical studies conducted from 2018 to 2022 and is integral to the successful filing and review of the submission. These studies were carried out in an aggregate total of 134 healthy and hypertensive persons and evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens. The studies also showed zero serious adverse effects, evidencing Lexaria’s DehydraTECH-CBD’s potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” said Chris Bunka, CEO of Lexaria (https://ibn.fm/Fiizr).

Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the IND application. However, work outside the company’s control remains delayed, including the provision of required documentation by a materials supplier and stability testing of the material. Despite this delay, Lexaria is still progressing toward its application submission.

The company is only aware of a handful of other published research investigating whether a decrease in resting blood pressure is possible following multiple weeks of oral CBD use. Lexaria notes that none of this published research has succeeded in achieving this goal. The outcomes of the company’s previous research prove DehydraTECH-CBD’s superior power to reduce blood pressure over oral CBD formulations.

Lexaria’s DehydraTECH technology is designed for formulating and delivering lipophilic drugs and active pharmaceutical ingredients (“APIs”). DehydraTECH increases their effectiveness and improves the way these APIs enter the bloodstream. The major benefits of a DehydraTECH-enabled drug or consumer product include:

• Faster delivery time – with the effects of the product felt in minutes
• Increased bioavailability – the technology is more effective at delivering a drug or product directly to the bloodstream
• Increased brain absorption – animal testing has suggested significant improvement in the quantity of the drug delivered across the blood-brain barrier
• Improved potency – more of the ingested product is made available to the body, with lower dosages necessary for the desired result
• Reduced administration costs – lower dosages mean less overall drug costs
• Masking unwanted tastes – the technology eliminates or reduces the need for sweeteners

DehydraTECH is suitable for use with various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, topicals and over-the-counter capsules, pills, tablets, and oral suspensions. The company’s technology is best considered an additional layer that can improve the effectiveness of existing drug offerings or planned new offerings. Lexaria’s DehydraTECH is covered by over 30 granted patents and has many more pending worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

DGE invites medical device design, safety, and compliance professionals to attend the 4th Human Factors Engineering & Usability Studies Congress to be held at The Bellevue Hotel, Philadelphia, PA, October 4-5, 2023. The distinguished event serves as a decisive knowledge-sharing platform focused on the complicated procedural, technical, and collaborative challenges that usability teams face.

The 4th Human Factors Engineering & Usability Studies Congress focuses on understanding and meeting FDA expectations, working with diverse user groups, recognizing the role of user fear and embarrassment, and determining just how much realistic detail is necessary for simulated use environments.

Improved User Experience and Regulatory Success

The 4th Human Factors Engineering & Usability Studies Congress aims to improve user experience and regulatory success through groundbreaking designs of medical devices, IFUs, and combination products. The event promises to delve into the importance of creating IFUs that align with user knowledge, ensuring the key information is coherent and logical.

The industry experts will share their perspectives and insights into the art of designing user interfaces that impart confidence in algorithmic device decisions. It’s an unmatched opportunity for attendees to connect with like-minded individuals and gain valuable knowledge about customizable device designs that rapidly adapt to formulation changes.

Registration for the event is now open. Interested participants should register for the 4th Human Factors Engineering & Usability Studies Congress and be a part of an innovative community driven toward medical transformation.

To learn more, please visit https://ibn.fm/0Knj7.